Eslicarbazepine

Summary

Eslicarbazepine (CHEMBL315985) is an approved small molecule (ATC N03AF04); indicated across 1 condition including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AF04
• Indications: 1 condition
• Clinical trials: 11
• Chemistry: 254.28 Da · C15H14N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL315985
Name	Eslicarbazepine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9881504
ATC	N03AF04
Molecular formula	C15H14N2O2
Molecular weight	254.28
InChIKey	BMPDWHIDQYTSHX-AWEZNQCLSA-N

SMILES: C1[C@@H](C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O

IUPAC name: (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide

Also known as: (s)-licarbazepine, BIA-2194, CGP-13751, Erelib, Eslicarbazepina, Eslicarbazepine, Licarbazepine, (s)-, Pazzul, Stedesa, ESLICARBAZEPINE

Patent coverage: 283 distinct patent families (660 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 544 (82%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	2
PHASE1	2
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02912364	PHASE4	COMPLETED	Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults
NCT00988156	PHASE3	COMPLETED	Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
NCT01091662	PHASE3	COMPLETED	Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
NCT01124097	PHASE3	TERMINATED	Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia
NCT01129960	PHASE3	TERMINATED	Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
NCT01162460	PHASE3	COMPLETED	Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures
NCT01527513	PHASE2	COMPLETED	Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures
NCT01824602	PHASE2	TERMINATED	Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder
NCT00898560	PHASE1	COMPLETED	Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive
NCT03116321	PHASE1	COMPLETED	Bioequivalence of Two Different Sources of Eslicarbazepine Acetate
NCT01587339	Not specified	COMPLETED	Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).